Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Scherlinger

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
Rheumatology (Oxford, England)|July 5, 2022
Inhibition of calcium/calmodulin-dependent protein kinase IV in arthritis: dual effect on Th17 cell activation and osteoclastogenesisTomohiro Koga, Masataka Umeda, Nobuya Yoshida, et al.
Arthritis Research & Therapy|July 14, 2021
Incidence and predictors of COVID-19 and flares in patients with rare autoimmune diseases: a systematic survey and serological study at a national reference center in FranceRenaud Felten, Marc Scherlinger, Aurélien Guffroy, et al.
Annals of the Rheumatic Diseases|March 6, 2026
Safety and efficacy of blinatumomab in the treatment of refractory systemic sclerosis: a case seriesMarc Scherlinger, Yannick Dieudonné, Stéphane Hilliquin, et al.
Joint Bone Spine|August 3, 2019
Osseous sarcoidosis: A multicenter retrospective case-control study of 48 patientsImen Ben Hassine, Christopher Rein, Cloé Comarmond, et al.
Autoimmunity Reviews|April 3, 2020
Worldwide trends in all-cause mortality of auto-immune systemic diseases between 2001 and 2014Marc Scherlinger, Philippe Mertz, Flora Sagez, et al.
JCI Insight|December 21, 2018
OX40L/OX40 axis impairs follicular and natural Treg function in human SLEClément Jacquemin, Jean-François Augusto, Marc Scherlinger, et al.
Infectious Diseases and Therapy|July 10, 2021
Refining "Long-COVID" by a Prospective Multimodal Evaluation of Patients with Long-Term Symptoms Attributed to SARS-CoV-2 InfectionMarc Scherlinger, Renaud Felten, Floriane Gallais, et al.
The Lancet. Rheumatology|March 29, 2025
CAR T-cell therapy in autoimmune diseases: where are we and where are we going?Marc Scherlinger, Gaetane Nocturne, Marko Radic, et al.
Science Translational Medicine|July 1, 2021
Selectins impair regulatory T cell function and contribute to systemic lupus erythematosus pathogenesisMarc Scherlinger, Vivien Guillotin, Isabelle Douchet, et al.
Seminars in Arthritis and Rheumatism|October 23, 2018
Characteristics and clinical outcomes after treatment of a national cohort of PCR-positive Lyme arthritisAntoine Grillon, Marc Scherlinger, Pierre-Hugues Boyer, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Rheumatology (Oxford, England)|July 5, 2022
Inhibition of calcium/calmodulin-dependent protein kinase IV in arthritis: dual effect on Th17 cell activation and osteoclastogenesisTomohiro Koga, Masataka Umeda, Nobuya Yoshida, et al.
Arthritis Research & Therapy|July 14, 2021
Incidence and predictors of COVID-19 and flares in patients with rare autoimmune diseases: a systematic survey and serological study at a national reference center in FranceRenaud Felten, Marc Scherlinger, Aurélien Guffroy, et al.
Annals of the Rheumatic Diseases|March 6, 2026
Safety and efficacy of blinatumomab in the treatment of refractory systemic sclerosis: a case seriesMarc Scherlinger, Yannick Dieudonné, Stéphane Hilliquin, et al.
Joint Bone Spine|August 3, 2019
Osseous sarcoidosis: A multicenter retrospective case-control study of 48 patientsImen Ben Hassine, Christopher Rein, Cloé Comarmond, et al.
Autoimmunity Reviews|April 3, 2020
Worldwide trends in all-cause mortality of auto-immune systemic diseases between 2001 and 2014Marc Scherlinger, Philippe Mertz, Flora Sagez, et al.
JCI Insight|December 21, 2018
OX40L/OX40 axis impairs follicular and natural Treg function in human SLEClément Jacquemin, Jean-François Augusto, Marc Scherlinger, et al.
Infectious Diseases and Therapy|July 10, 2021
Refining "Long-COVID" by a Prospective Multimodal Evaluation of Patients with Long-Term Symptoms Attributed to SARS-CoV-2 InfectionMarc Scherlinger, Renaud Felten, Floriane Gallais, et al.
The Lancet. Rheumatology|March 29, 2025
CAR T-cell therapy in autoimmune diseases: where are we and where are we going?Marc Scherlinger, Gaetane Nocturne, Marko Radic, et al.
Science Translational Medicine|July 1, 2021
Selectins impair regulatory T cell function and contribute to systemic lupus erythematosus pathogenesisMarc Scherlinger, Vivien Guillotin, Isabelle Douchet, et al.
Seminars in Arthritis and Rheumatism|October 23, 2018
Characteristics and clinical outcomes after treatment of a national cohort of PCR-positive Lyme arthritisAntoine Grillon, Marc Scherlinger, Pierre-Hugues Boyer, et al.
Pageof 8